EKF Diagnostics Showcases Range of Diabetes and Hematology POC Devices
|
By LabMedica International staff writers Posted on 01 Aug 2024 |
EKF Diagnostics (Cardiff, Wales, UK) is showcasing its range of diabetes and hematology point-of-care (POC) devices and connectivity software at ADLM 2024.
Among its diabetes POC devices, EKF is highlighting the Quo-Lab HbA1c semi-automated desktop POC analyzer for measuring glycated hemoglobin (HbA1c). The semi-automated analyzer has been designed specifically to meet the needs of diabetes clinics and laboratories in settings that demand low cost of operation and ease of use. EKF is also showcasing the Quo-Test fully automated desktop POC analyzer designed for easy and reliable HbA1c measurement for the monitoring and management of diabetes in a POC setting such as diabetes clinics and doctors’ surgeries. This fully automated hemoglobin A1c analyzer uses patented boronate affinity fluorescence quenching technology to measure glycated hemoglobin from a 4 μl sample taken from a capillary or venous whole blood. Also featuring at the show is the STAT-Site WB analyzer for the quantitative determination of β-ketones (Beta-Hydroxybutyrate or β-HB) and glucose in whole blood taken from capillary or venous samples.
Additionally, EKF is presenting its newly launched Biosen C-Line, an advanced version of its industry-leading rapid benchtop glucose and lactate analyzer. The new and updated analyzer has been designed to enhance usability with the latest color, touch screen, and advanced connectivity, enabling the Biosen C-Line to seamlessly connect with hospital and laboratory IT systems, via EKF Link, to ensure patient results are quickly and securely available to clinicians. Visitors to the EKF booth at the show can also experience the EKF Link middleware solution for healthcare providers that is designed to manage their POC analyzers and the generated data on one centralized platform. EKF Link is a flexible, open solution that can be interfaced with most vendors’ POC analyzers to permit the real-time management of data including patient test results, QC results, operator management, and analyzer configuration.
Within its portfolio of hematology POC devices, EKF is highlighting the DiaSpect Tm hand-held hemoglobin analyzer which is now powered by EKF Link, enabling new functions like hematocrit calculation, quality control management, and patient data management functions. The proven technology of DiaSpect Tm delivers laboratory-quality results in one second from the microcuvette being placed into the analyzer. In addition, EKF is featuring the Hemo Control POC hemoglobin analyzer which is designed to provide quantitative, lab-quality hemoglobin results in 25 seconds. Also featuring at the show is the HemataStat II microhematocrit centrifuge that provides a quantitative hematocrit reading for up to six blood samples from one 60-second spin.
Related Links:
EKF Diagnostics
Latest ADLM 2024 News
- HemoSonics Demonstrates Breakthrough in Point-Of-Care Viscoelastic Hemostasis Testing
- Cytovale Demonstrates 8-Minute Sepsis Diagnostic Test
- Inpeco Launches Next-Generation Total Lab Automation System
- Messe Düsseldorf Promotes International “MEDICAlliance” Portfolio at ADLM 2024
- Tianlong Showcases Latest Products in Molecular Diagnostics, Biochemistry, Immunology and POC Testing
- QuidelOrtho Demonstrates Advanced Diagnostic Laboratory Solutions across Healthcare Continuum
- HORIBA Unveils New Compact Hematology Analyzers with Combined ESR and CBC/Diff
- Beckman Coulter Introduces Latest Innovations in Clinical Diagnostics
- Abbott Demonstrates End to End Laboratory Solutions
- Werfen Introduces GEM Premier 7000 with iQM3 Blood Gas Testing System
- Thermo Fisher Showcases Diagnostics Innovation Across Therapeutic Areas
- Siemens Demonstrates Human-Centered Engineering and Automation for Laboratory Testing
- Roche Showcases Solutions for Laboratories of the Future
- POC Electrical Sensing-Based Blood Testing Technology Unveiled at ADLM 2024

- World's First 5-Minute Real-Time PCR Instrument Debuts at ADLM 2024
- ADLM 2024 Showcases Breakthrough Innovations Shaping Future of Clinical Testing
Channels
Clinical Chemistry
view channel
Noninvasive Urine Test May Support Earlier Diagnosis of Psychiatric Disorders
Delays in diagnosing serious psychiatric conditions can leave patients without timely support and complicate treatment planning. For bipolar disorder, average time to diagnosis can exceed nine years, and... Read moreAt-Home Blood and Cognitive Tests Support Dementia Risk Stratification
Dementia places a substantial burden on patients and health systems, and identifying individuals at elevated risk remains difficult at scale. In the UK, almost a million people are estimated to be living... Read moreMolecular Diagnostics
view channel
Emerging Biomarkers Advance Early Detection of MASLD and Liver Cancer Risk
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects about 30% of people worldwide and can advance to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis, and... Read more
Patented Isothermal Amplification Chemistry Advances Decentralized Testing
Molecular diagnostics offer high sensitivity for pathogen detection but typically rely on thermal cycling and specialized instruments, limiting their use outside centralized laboratories.... Read more
Finger-Prick Blood Test Aids Early Tuberculosis Detection and Risk Stratification
Household contacts of people with tuberculosis face an estimated 2% risk of developing disease, yet most are asymptomatic at the time of screening. Early-stage cases are often missed because symptom checks... Read more
Urine Test Beats MRI in Identifying Prostate Cancer Upgrading During Active Surveillance
Active surveillance is common for men with low-risk prostate cancer, yet deciding when to repeat biopsy remains challenging. Prostate-specific antigen (PSA) testing and magnetic resonance imaging (MRI)... Read moreHematology
view channel
Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is an aggressive blood cancer that most often affects older adults and still carries a poor prognosis despite therapeutic advances. Venetoclax-based regimens have improved... Read more
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read moreImmunology
view channel
Biomarkers and Molecular Testing Advance Precision Allergy Care
Allergic diseases often present with similar symptoms but can be driven by distinct biological mechanisms, making standardized care inefficient for many patients. Historically, individuals with pollen... Read more
Point-of-Care Tests Could Expand Access to Mpox Diagnosis
Mpox outbreaks in non-endemic regions have underscored the need for rapid, accessible diagnostics to limit transmission. Polymerase chain reaction (PCR) remains the clinical reference, yet it depends on... Read moreMicrobiology
view channel
Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
Tuberculosis remains a major global health challenge and continues to drive significant morbidity and mortality. The World Health Organization’s 2024 global report cites it as the leading cause of death... Read more
Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
Early detection of gastric cancer could be advanced by scalable screening strategies using minimally invasive sampling. Saliva collection is noninvasive and cost-effective, supporting wider adoption... Read morePathology
view channel
FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
Risk assessment at diagnosis is central to guiding therapy for early-stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) invasive breast cancer, where overtreatment... Read more
New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
Pathologists worldwide rely on hematoxylin and eosin (H&E) slides to examine tissue architecture, yet these stains do not reveal the underlying molecular activity that often drives disease.... Read moreTechnology
view channel
Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing
Latent tuberculosis remains a substantial testing workload for clinical laboratories as screening programs expand. Despite this growth, only about 40% of testing has shifted from traditional skin tests... Read more
Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
Pancreatic cancer remains one of the hardest malignancies to treat because tumors are embedded within a dense microenvironment that shapes growth and therapy response. Standard laboratory models often... Read moreIndustry
view channel
Roche to Acquire PathAI for Up to $1.05 Billion to Strengthen AI Diagnostics Portfolio
Roche has entered into a definitive merger agreement to acquire PathAI, a company focused on digital pathology and artificial intelligence for pathology laboratories and the biopharma industry.... Read more









